FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3164812668> ?p ?o ?g. }

• W3164812668 abstract "Chronic migraine (CM) is associated with substantial economic burden. Real-world data suggests that onabotulinumtoxinA treatment for CM reduces healthcare resource utilisation (HRU) and related costs.REPOSE was a 2-year prospective, multicentre, non-interventional, observational study to describe the real-world use of onabotulinumtoxinA in adult patients with CM. This analysis examined the impact of onabotulinumtoxinA on HRU. Patients received onabotulinumtoxinA treatment approximately every 12 weeks according to their physicians' discretion, guided by the summary of product characteristics (SPC) and PREEMPT injection paradigm. HRU outcome measures were collected at baseline and all administration visits and included headache-related hospitalizations and healthcare professional (HCP) visits. Health economic data, including family doctor and specialist visits, inpatient treatment for headache, acupuncture, technical diagnostics, use of nonpharmacologic remedies, and work productivity were also collected for patients enrolled at German study centres.Overall, 641 patients were enrolled at 78 study centres across 7 countries (Germany, UK, Italy, Spain, Norway, Sweden, and Russia), 633 received ≥1 onabotulinumtoxinA dose, and 128 completed the 2-year study. Patients were, on average, aged 45 years, 85% were female, and 60% (n = 377) were from Germany. At the end of the 2-year observation period, significantly fewer patients reported headache-related hospitalizations (p < 0.02) and HCP visits (p < 0.001) within the past 3 months than in the 3 months before baseline. In the German population, reductions were observed across all health services at all follow-up visits compared with baseline. The percentage of patients who saw a family doctor decreased from 41.7% at baseline to 13.5% at administration visit 8 and visits to a medical specialist decreased from 61.7% to 5.2% of patients. Inpatient acute treatment and technical diagnostics declined from 6.4% and 19.7% of patients at baseline to 0.0% and 1.0% at administration 8, respectively. The use of nonpharmacologic remedies and medication for the acute treatment of migraine also decreased with continued onabotulinumtoxinA treatment. Work incapacity, disability, absenteeism, and impaired performance at school/work improved with onabotulinumtoxinA treatment for CM over the 2-year observation period.Real-world evidence from REPOSE demonstrates that onabotulinumtoxinA treatment is associated with decreased HRU and supports the long-term benefits associated with the use of onabotulinumtoxinA for CM in clinical practice.NCT01686581 . Name of registry: ClinicalTrials.gov. URL of registry: Date of retrospective registration: September 18, 2012. Date of enrolment of first patient: July 23, 2012." @default.
• W3164812668 created "2021-06-07" @default.
• W3164812668 creator A5043387946 @default.
• W3164812668 creator A5069865671 @default.
• W3164812668 creator A5074433389 @default.
• W3164812668 creator A5083322806 @default.
• W3164812668 date "2021-06-02" @default.
• W3164812668 modified "2023-10-14" @default.
• W3164812668 title "Real-life use of onabotulinumtoxinA reduces healthcare resource utilization in individuals with chronic migraine: the REPOSE study" @default.
• W3164812668 cites W1968001773 @default.
• W3164812668 cites W1994481205 @default.
• W3164812668 cites W2007410119 @default.
• W3164812668 cites W2029991935 @default.
• W3164812668 cites W2046085057 @default.
• W3164812668 cites W2086716404 @default.
• W3164812668 cites W2087789299 @default.
• W3164812668 cites W2087897540 @default.
• W3164812668 cites W2094473459 @default.
• W3164812668 cites W2106177437 @default.
• W3164812668 cites W2115337076 @default.
• W3164812668 cites W2123954268 @default.
• W3164812668 cites W2142670324 @default.
• W3164812668 cites W2147428560 @default.
• W3164812668 cites W2149233088 @default.
• W3164812668 cites W2306566431 @default.
• W3164812668 cites W2330209124 @default.
• W3164812668 cites W2342476204 @default.
• W3164812668 cites W2410664321 @default.
• W3164812668 cites W2751422351 @default.
• W3164812668 cites W2786230526 @default.
• W3164812668 cites W2801085490 @default.
• W3164812668 cites W2912654919 @default.
• W3164812668 cites W2915785520 @default.
• W3164812668 cites W2929053468 @default.
• W3164812668 cites W2968888063 @default.
• W3164812668 cites W2979073826 @default.
• W3164812668 cites W2997427223 @default.
• W3164812668 cites W3048805137 @default.
• W3164812668 cites W3083977966 @default.
• W3164812668 cites W3149613859 @default.
• W3164812668 cites W4230120862 @default.
• W3164812668 doi "https://doi.org/10.1186/s10194-021-01260-4" @default.
• W3164812668 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8173963" @default.
• W3164812668 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34078259" @default.
• W3164812668 hasPublicationYear "2021" @default.
• W3164812668 type Work @default.
• W3164812668 sameAs 3164812668 @default.
• W3164812668 citedByCount "10" @default.
• W3164812668 countsByYear W31648126682022 @default.
• W3164812668 countsByYear W31648126682023 @default.
• W3164812668 crossrefType "journal-article" @default.
• W3164812668 hasAuthorship W3164812668A5043387946 @default.
• W3164812668 hasAuthorship W3164812668A5069865671 @default.
• W3164812668 hasAuthorship W3164812668A5074433389 @default.
• W3164812668 hasAuthorship W3164812668A5083322806 @default.
• W3164812668 hasBestOaLocation W31648126681 @default.
• W3164812668 hasConcept C121955636 @default.
• W3164812668 hasConcept C126322002 @default.
• W3164812668 hasConcept C144133560 @default.
• W3164812668 hasConcept C160735492 @default.
• W3164812668 hasConcept C162324750 @default.
• W3164812668 hasConcept C1862650 @default.
• W3164812668 hasConcept C187212893 @default.
• W3164812668 hasConcept C194828623 @default.
• W3164812668 hasConcept C23131810 @default.
• W3164812668 hasConcept C2778541695 @default.
• W3164812668 hasConcept C2908647359 @default.
• W3164812668 hasConcept C2910587157 @default.
• W3164812668 hasConcept C50522688 @default.
• W3164812668 hasConcept C6964187 @default.
• W3164812668 hasConcept C71924100 @default.
• W3164812668 hasConcept C99454951 @default.
• W3164812668 hasConceptScore W3164812668C121955636 @default.
• W3164812668 hasConceptScore W3164812668C126322002 @default.
• W3164812668 hasConceptScore W3164812668C144133560 @default.
• W3164812668 hasConceptScore W3164812668C160735492 @default.
• W3164812668 hasConceptScore W3164812668C162324750 @default.
• W3164812668 hasConceptScore W3164812668C1862650 @default.
• W3164812668 hasConceptScore W3164812668C187212893 @default.
• W3164812668 hasConceptScore W3164812668C194828623 @default.
• W3164812668 hasConceptScore W3164812668C23131810 @default.
• W3164812668 hasConceptScore W3164812668C2778541695 @default.
• W3164812668 hasConceptScore W3164812668C2908647359 @default.
• W3164812668 hasConceptScore W3164812668C2910587157 @default.
• W3164812668 hasConceptScore W3164812668C50522688 @default.
• W3164812668 hasConceptScore W3164812668C6964187 @default.
• W3164812668 hasConceptScore W3164812668C71924100 @default.
• W3164812668 hasConceptScore W3164812668C99454951 @default.
• W3164812668 hasIssue "1" @default.
• W3164812668 hasLocation W31648126681 @default.
• W3164812668 hasLocation W31648126682 @default.
• W3164812668 hasLocation W31648126683 @default.
• W3164812668 hasOpenAccess W3164812668 @default.
• W3164812668 hasPrimaryLocation W31648126681 @default.
• W3164812668 hasRelatedWork W1995699180 @default.
• W3164812668 hasRelatedWork W2022676424 @default.
• W3164812668 hasRelatedWork W2029991935 @default.
• W3164812668 hasRelatedWork W2242550496 @default.
• W3164812668 hasRelatedWork W2260435540 @default.
• W3164812668 hasRelatedWork W2346408229 @default.

• next